The Max dimerization protein 3 (MXD3), member of MAD family, has been considered a potential target for therapeutic treatment of brain and central nervous system cancers due to its role in cellular proliferation and tumorigenesis (Barisone et al., 2012). Here, MXD3 is linked to central nervous system cancer.